Novozymes prevails in patent trial against Danisco
A ruling was issued in the US legal proceedings between Novozymes and Danisco. Novozymes won the case which has lasted 1½ years and concerned an infringement of one of Novozymes´patents on enzymes for bioethanol. The case started in the fall of 2004 when Novozymes discovered that Genencor International Inc (later bought by Danisco) was selling enzymes protected by Novozymes´patent rights to the American ethanol market.
Kristian Merser, general counsel in Novozymes states: "We are very pleased with the decision but we are obviously annoyed by the harm the patent infringement has caused on our market for biofuel enzymes. It´s very satisfactory that the court agreed that our patent is valid and has been infringed - considering the large amount of resources we use on research, development and patenting."
Danisco announced that the company has withdrawn the product that infringed Novozymes' patent (Spezyme(R) Ethyl) from the market. The size of the damages will be decided in the fall. Novozymes has claimed several million US dollars in damages for loss of profits.
Most read news
Other news from the department politics & laws

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Novel biomarker score could help measure adherence to Mediterranean diet - New evidence suggests Mediterranean diet may reduce type 2 diabetes risk more than previously thought
ProtAffin AG signs manufacturing contract for PA401 with CMC Biologics A/S
RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks
The OakLabs GmbH receives High-Tech Gründerfonds seed funding for intelligent breeding methods
City_of_Hope_National_Medical_Center
Leigh's_disease
Hepatopulmonary_syndrome

ZEISS Invests by Acquiring Majority Stake in arivis AG - ZEISS further expands its imaging technology capabilities for research microscopy with 3D and big image data software expertise
Modern Bioscience PLC and the University of Dundee to develop novel cancer drug - Re-profiling of rimcazole as an anti-cancer drug based on pioneering science at Dundee
